Literature DB >> 20378752

Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.

Gunnar Cario1, Martin Zimmermann, Renja Romey, Stefan Gesk, Inga Vater, Jochen Harbott, André Schrauder, Anja Moericke, Shai Izraeli, Takashi Akasaka, Martin J S Dyer, Reiner Siebert, Martin Schrappe, Martin Stanulla.   

Abstract

High-level expression of the cytokine receptor-like factor 2 gene, CRLF2, in precursor B-cell acute lymphoblastic leukemia (pB-ALL) was shown to be caused by a translocation involving the IGH@ locus or a deletion juxtaposing CRLF2 with the P2RY8 promoter. To assess its possible prognostic value, CRLF2 expression was analyzed in 555 childhood pB-ALL patients treated according to the Acute Lymphoblastic Leukemia Berlin-Frankfurt-Münster 2000 (ALL-BFM 2000) protocol. Besides CRLF2 rearrangements, high-level CRLF2 expression was seen in cases with supernumerary copies of the CRLF2 locus. On the basis of the detection of CRLF2 rearrangements, a CRLF2 high-expression group (n = 49) was defined. This group had a 6-year relapse incidence of 31% plus or minus 8% compared with 11% plus or minus 1% in the CRLF2 low-expression group (P = .006). This difference was mainly attributable to an extremely high incidence of relapse (71% +/- 19%) in non-high-risk patients with P2RY8-CRLF2 rearrangement. The assessment of CRLF2 aberrations may therefore serve as new stratification tool in Berlin-Frankfurt-Münster-based protocols by identifying additional high-risk patients who may benefit from an intensified and/or targeted treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378752     DOI: 10.1182/blood-2009-11-256131

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  77 in total

Review 1.  Genomic profiling of B-progenitor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-06       Impact factor: 3.020

Review 2.  Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Stephanie McGregor; Jennifer McNeer; Sandeep Gurbuxani
Journal:  Semin Diagn Pathol       Date:  2012-02       Impact factor: 3.464

Review 3.  Acute leukemia in children with Down syndrome.

Authors:  Ana C Xavier; Jeffrey W Taub
Journal:  Haematologica       Date:  2010-07       Impact factor: 9.941

Review 4.  Emerging technologies in paediatric leukaemia.

Authors:  Amanda Dixon-McIver
Journal:  Transl Pediatr       Date:  2015-04

5.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

Authors:  Shalini C Reshmi; Richard C Harvey; Kathryn G Roberts; Eileen Stonerock; Amy Smith; Heather Jenkins; I-Ming Chen; Marc Valentine; Yu Liu; Yongjin Li; Ying Shao; John Easton; Debbie Payne-Turner; Zhaohui Gu; Thai Hoa Tran; Jonathan V Nguyen; Meenakshi Devidas; Yunfeng Dai; Nyla A Heerema; Andrew J Carroll; Elizabeth A Raetz; Michael J Borowitz; Brent L Wood; Anne L Angiolillo; Michael J Burke; Wanda L Salzer; Patrick A Zweidler-McKay; Karen R Rabin; William L Carroll; Jinghui Zhang; Mignon L Loh; Charles G Mullighan; Cheryl L Willman; Julie M Gastier-Foster; Stephen P Hunger
Journal:  Blood       Date:  2017-04-13       Impact factor: 22.113

Review 6.  Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia.

Authors:  Olivia L Francis; Terry-Ann M Milford; Cornelia Beldiman; Kimberly J Payne
Journal:  J Investig Med       Date:  2016-02-12       Impact factor: 2.895

Review 7.  Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.

Authors:  Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

Authors:  Christopher J Ott; Nadja Kopp; Liat Bird; Ronald M Paranal; Jun Qi; Teresa Bowman; Scott J Rodig; Andrew L Kung; James E Bradner; David M Weinstock
Journal:  Blood       Date:  2012-08-17       Impact factor: 22.113

9.  A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.

Authors:  Olivia L Francis; Terry-Ann M Milford; Shannalee R Martinez; Ineavely Baez; Jacqueline S Coats; Karina Mayagoitia; Katherine R Concepcion; Elizabeth Ginelli; Cornelia Beldiman; Abigail Benitez; Abby J Weldon; Keshav Arogyaswamy; Parveen Shiraz; Ross Fisher; Christopher L Morris; Xiao-Bing Zhang; Valeri Filippov; Ben Van Handel; Zheng Ge; Chunhua Song; Sinisa Dovat; Ruijun Jeanna Su; Kimberly J Payne
Journal:  Haematologica       Date:  2015-11-26       Impact factor: 9.941

10.  Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic.

Authors:  Charles G Mullighan; Cheryl L Willman
Journal:  J Adolesc Young Adult Oncol       Date:  2011-06       Impact factor: 2.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.